Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cerebral arterial thrombosis treatment drug

A technology for treating ischemic stroke and drugs, which can be used in drug combinations, pharmaceutical formulas, plant raw materials, etc., and can solve the problem of low curative effect

Inactive Publication Date: 2016-12-07
丁静
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention aims at the technical defects of the prior art, and provides a drug for treating ischemic stroke, so as to solve the technical problem of low curative effect of related drugs in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cerebral arterial thrombosis treatment drug
  • Cerebral arterial thrombosis treatment drug
  • Cerebral arterial thrombosis treatment drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] A drug for treating ischemic stroke, characterized in that the composition is composed of the following components by weight: 0.0085 parts of tenofovir disoproxil, 5.5 parts of hydrangea, 2.1 parts of castor bean, 1.3 parts of white wax, goose tube 1.7 parts of stone, 1.6 parts of gorse root, 1.2 parts of chicken vine, 1.1 parts of chaga, 1.4 parts of braised vegetables, 1.5 parts of Guanglingxiang, 1.4 parts of white peony, 1.1 parts of Gastrodia elata, 1.5 parts of Codonopsis, 1.8 parts of walnut kernel.

[0027] 1. Selection of experimental objects

[0028] Randomly select 100 patients with onset time of more than 4.5 hours but less than 48 hours as experimental subjects, patients with large artery atherosclerosis and lacunar necrosis with necrosis volume exceeding 5ml, and without arrhythmia, macular edema, tumor and immunosuppression The patients who received the drug were used as the experimental subjects, and 100 people were matched with clinical and imaging char...

Embodiment 2

[0037] A drug for treating ischemic stroke, characterized in that the composition consists of the following components by weight: 0.009 parts of tenofovir disoproxil, 5 parts of hydrangea, 2.5 parts of castor bean, 1.5 parts of white wax, goose tube 1.5 parts of stone, 1.5 parts of gorse root, 1.5 parts of chicken vine, 1.5 parts of Chaga fungus, 1.5 parts of welding vegetable, and 1.5 parts of Guanglingxiang.

Embodiment 3

[0039] A medicine for treating ischemic stroke, comprising the following ingredients in parts by weight: 0.008 parts of tenofovir disoproxil, 4 parts of hydrangea, 2 parts of castor bean, 1 part of chrysanthemum, 1 part of gooseberry, and 1 part of gorse root 1 part of Chicken Yateng, 1 part of Chaga Mushroom, 1 part of Welted Vegetable, and 1 part of Guanglingxiang.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a cerebral arterial thrombosis treatment drug. Experiments verify that tenofovir disoproxil fumarate and structural analogues thereof have the effect of treating inflammation by means of relief by lymphocytes infiltration caused by cerebral arterial thrombosis, and further achieve the effect of treating cerebral arterial thrombosis. On the basis, added natural drugs further improve the curative effect level, and particularly the selected ingredients do not have direct treatment or regulating effect on the respective cerebral blood supply system and the cerebral arterial thrombosis on the existing medical perceive level. Under this condition, the applicants accidentally discover that the traditional Chinese medicine composition obtained by integration of the ingredients and optimal design of the dosage of the ingredients can effectively regulate the cardiovascular functions and promote cardiac blood supply to further achieve the effect of treating cerebral arterial thrombosis, and has the advantages of quickness in taking effect, no side effect and the like.

Description

technical field [0001] The invention relates to the technical field of treating cerebrovascular diseases, and relates to a medicine for treating ischemic stroke. Background technique [0002] Ischemic stroke refers to brain tissue necrosis disease caused by stenosis or occlusion of cerebral blood supply arteries (carotid artery and vertebral artery) and insufficient cerebral blood supply. It is the main type of cerebrovascular disease, accounting for about 85% of the total number of stroke cases. %. Due to the suddenness of this disease and the serious pathological damage, it often causes irreversible damage to brain tissue unless it is discovered in time and treated. The treatment methods for ischemic stroke in the prior art mainly include thrombolytic therapy, anticoagulation, neuroprotection, surgery, etc. However, clinically, unless thrombolysis is effective within 4.5 hours, other methods are difficult to significantly improve the condition , high disability or fatali...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/8988A61K36/74A61P9/10A61K31/675A61K33/06A61K35/64
CPCA61K36/8988A61K31/675A61K33/06A61K35/63A61K36/07A61K36/185A61K36/232A61K36/31A61K36/344A61K36/46A61K36/47A61K36/48A61K36/52A61K36/734A61K36/74A61K2300/00
Inventor 丁静李银柱
Owner 丁静
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com